Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Buti M., Tsai N., Petersen J., Flisiak R., GÜREL S., Krastev Z., ...More

DIGESTIVE DISEASES AND SCIENCES, vol.60, no.5, pp.1457-1464, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 60 Issue: 5
  • Publication Date: 2015
  • Doi Number: 10.1007/s10620-014-3486-7
  • Journal Name: DIGESTIVE DISEASES AND SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1457-1464
  • Keywords: Antiviral agent, Cirrhosis, Hepatitis B e antigen, Liver disease, LONG-TERM EFFICACY, ADEFOVIR DIPIVOXIL, ENTECAVIR TREATMENT, NAIVE PATIENTS, LAMIVUDINE, CIRRHOSIS, RISK
  • Bursa Uludag University Affiliated: Yes

Abstract

Background Long-term tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB) is associated with sustained viral suppression and regression of fibrosis and cirrhosis at year 5 (240 weeks) and no TDF resistance through 6 years (288 weeks).